APRE 8-K: SEC filing

Aprea Therapeutics

Filed with the SEC on · accession 0001104659-26-130446

APRE filed a 8-K (current report) with the SEC on Nov 20, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Aprea Therapeutics announced updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational oral selective WEE1 inhibitor, and updated its corporate presentation slide deck.

Key details

RegistrantAprea Therapeutics, Inc.
President and chief executive officerOren Gilad, Ph.D.

✦ Ask GOAX AI about this filing — what it means for APRE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for APRE?

Click here

Frequently asked questions

What did APRE file with the SEC on Nov 20, 2026?

APRE filed a 8-K (SEC filing). Aprea Therapeutics announced updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational oral selective WEE1 inhibitor, and updated its corporate presentation slide deck.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other APRE SEC filings

Get alerts when APRE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days